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In an epidemiologic investigation of respiratory infec-
tions in Italy, October 2008–September 2009, we tested 
samples from patients for respiratory viruses.  Human en-
terovirus genotype EV-104 (identiﬁ  ed in Switzerland) was 
found in 3 immunocompromised and 2 immunocompetent 
patients. EV-104 is closely related to human rhinoviruses; 
thus, both types of viruses should be sought in respiratory 
syndromes.
H
uman rhinoviruses (HRVs) and enteroviruses (HEVs) 
have been grouped within the same genus (Enterovi-
rus) because of their identical genomic organization and 
high sequence homology (1). However, HRVs infect pri-
marily the respiratory tract, whereas HEVs infect primar-
ily the gastrointestinal tract, from which they can spread to 
distant sites, such as the central nervous system or myocar-
dial tissue. In addition, HRVs and HEVs differ in several 
in vitro properties, such as cell tropism, optimal growth 
temperature, and low pH sensitivity. Notwithstanding these 
different characteristics, some HEVs possess a respiratory 
tract tropism similar to that of HRVs; they infect both in-
fants and adults and cause infections of the upper and lower 
respiratory tracts. Several HEV genotypes, including en-
terovirus 68; coxsackieviruses (CVs) A9, A21, B2, and B4; 
and echoviruses 9 and 11, have reportedly been recovered 
from respiratory secretions or from tissues of patients with 
bronchitis, bronchiolitis, or pneumonia (2–6). In an extend-
ed epidemiologic study of HEV respiratory infections in 
children in France in 2008, respiratory syndromes were the 
second most common HEV-induced pathologic condition 
after meningitis (31% vs. 44%); HEV caused infections of 
the lower respiratory tract in 43 (54%) of 79 respiratory 
infections (7).
In Switzerland during 2004–2007, a new enterovirus 
genotype, EV-104, was reported in association with respi-
ratory signs and symptoms and acute otitis media in 8 chil-
dren from various regions of the country (8). In the past, 
this virus probably escaped detection because cell cultures 
lacked sensitivity or because appropriate molecular meth-
ods were not used. In addition, only a small percentage of 
detected HEVs are actually typed. EV-104 belongs to the 
HEV-C species, and its closest serotypes are CV-A19, CV-
A22, and CV-A1 (9).
The Study
During an epidemiologic survey conducted from Octo-
ber 1, 2008, through September 30, 2009, of viral infections 
of the respiratory tract, in which we collected respiratory 
samples from all patients admitted to our University Hos-
pital, Fondazione Istituto Di Ricovero e Cura a Carattere 
Scientiﬁ  co (IRCCS) Policlinico San Matteo, we detected 
5 strains of the new EV-104 genotype. The 5 Pavia (Pav) 
strains were neither temporally nor epidemiologically relat-
ed to each other and were recovered from 2 immunocompe-
tent patients (Pav-2 and Pav-4) and 3 immunocompromised 
patients (Pav-1, Pav-3, and Pav-5) (Table).
All respiratory secretion samples (1,500) were rou-
tinely tested for respiratory viruses (10). In addition, 
they were tested by real-time reverse transcription–PCR 
(RT-PCR) for ampliﬁ   cation and quantiﬁ   cation of both 
HEVs (11) and HRVs (12). Primers and probes used 
for HRV and HEV detection in this study were the fol-
lowing: HRV-forward 5′-CPXGCCZGCGTGGC-3′, 
HRV-reverse 5′-GAAACACGGACACCCAAAGTA-3′, 
HRV-probe 5′-TCCTCCGGCCCCTGAATGYGGC-3′, 
HEV-forward 5′-CCTCCGGCCCCTGA-3′, HEV-reverse 
5′-GATTGTCACCATAAGCAGCC-3′, and HEV-probe 
5′-CGGAACCGACTACTTTGGGT-3′. However, the 
HEV assay (11) does exhibit several mismatches with EV-
104 target.
Using these 2 assays, we detected 5 strains from 5 pa-
tients; these strains were ampliﬁ  ed to a comparable degree. 
When these 5 strains were tentatively ampliﬁ  ed in the viral 
protein (VP) 1 region (13), no amplicon was obtained, as re-
ported by others (8). Ampliﬁ  cation products were obtained 
when typing was attempted by amplifying the VP4/VP2 
region (14), which yielded a sequence resembling HEV-C 
genotypes but did not match any of the sequences pub-
lished in GenBank. Upon request, the new EV-104 strain 
(9) sequence was received from the researchers in Swit-
zerland (GenBank accession no. EU840733). Comparison 
of the sequences from the strains from Switzerland and the 
Pav strains showed that the 5 new Pav strains belonged to 
genotype EV-104 within the HEV-C species (GenBank ac-
cession nos. Pav-5, GU722097; Pav-4, GU722098; Pav-3, 
GU722099; Pav-2, GU722100; Pav-1, GU722101).
From the 5 new Pav strains, a 637-nt fragment was ob-
tained. In detail, 181 nt were within the 5′ noncoding region, 
207 in VP4, and 249 in VP2. The nucleotide identity within 
the 5 Pav strains was in the range of 97.9%–99.3%, and 
the identity with the reference strain from Switzerland was 
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95.4%–97.0%. Amino acid identity among the Pav strains 
was 100% for 4 strains; Pav-5 strain showed a 2-aa differ-
ence, and the amino acid identity for all Pav strains with the 
strain found in Switzerland was 98.1%–99.4%. Within the 
HEV-C species, the closest genotypes are CV-A19, CV-
A1, and CV-A22 with a nucleotide identity of 63%, 59%, 
and 62% and an amino acid identity of 81%, 80%, and 81% 
with the Pav strains, respectively (Figure 1).
In the 2 immunocompetent persons, EV-104 was asso-
ciated with episodes of chronic rhinopharyngitis, whereas 
3 immunocompromised patients exhibited symptoms of 
acute respiratory tract infection (Table). However, in the 
patient infected with Pav-5, a hematopoietic stem cell 
transplant recipient, at the beginning of a 4-month follow-
up after the transplant, respiratory syncytial virus was de-
tected in association with EV-104 and was likely respon-
sible for the acute respiratory symptoms (Figure 2) in the 
immediate posttransplant period. Subsequently, respiratory 
syncytial virus disappeared, while EV-104 remained at the 
same stable level (cycle threshold 24–29) during the entire 
follow-up period. In the last month of the follow-up period, 
EV-104 was not associated with any clinical or respiratory 
symptoms. Because we did not grow the virus in cell cul-
tures, we cannot exclude that our real-time RT-PCR assay 
may have detected only RNA left over from the EV-104 
infection. Even in the patient infected with Pav-5, we could 
not detect any mutation in several samples examined dur-
ing the 4 months of follow-up.
Conclusions
The 5 EV-104 strains from Italy, along with the refer-
ence strain from Switzerland, form a separate clade within 
the HEV-C species, which includes 3 polioviruses, several 
CV-A genotypes, EV-99, and EV-102 (Figure 1). The new 
HEV genotype conﬁ   rms the close relationship between 
HRVs and HEVs, and these ﬁ  ndings suggest that both spe-
cies of viruses should be sought in respiratory syndromes 
(8). Although the EV-104 strains detected in Switzerland 
were in children from different regions and covered a period 
of 4 years (8), our 5 strains were detected during a short pe-
riod of the same year and in the same geographic area; the 
patients, however, had presumably not been in contact with 
one another. However, population-based studies are needed 
to infer the actual prevalence of EV-104 infections.
In the patients reported here, only the upper respiratory 
tract was involved in the EV-104 infection, whereas in the 
study in Switzerland, otitis media and pneumonia were also 
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Table. Characteristics of 5 patients with HEV genotype EV-104 infection, Pavia, Italy, 2009* 
Patient
no. Sample no.
Age,
y/sex
Hospital department, 
date of admission 
Respiratory 
secretion Ct value
Clinical symptoms
Underlying 
disease
Virus identified/ 
coinfecting
virus (Ct) HEV HRV
Pav-1 NPA/9210 60/M Hematology 
outpatient, Apr
29.67 Undetected Fever, cough, 
rhinorrhea
HSCT (AML) EV-104
Pav-2 NPA/9570 62/M Infectious Diseases 
outpatient, Apr 
23.06 23.05 Chronic
rhinopharyngitis
None EV-104
Pav-3 NPA/11228 7/F Pediatric
Oncohematology, 
May 
33.64 Undetected Fever, rhinorrhea, 
conjunctivitis
AML
(chemotherapy)
EV-104
Pav-4 NPA/11230 37/F Infectious Diseases 
outpatient, May 
32.60 Undetected Chronic
rhinopharyngitis
None EV-104
Pav-5 NPA/13174 2/M Pediatric
Oncohematology, Jun
23.78 31.61 Cough, rhinorrhea, 
diarrhea, wheezing
HSCT (AML) EV-104/RSV
(18.53)
*HEV, human enterovirus; Ct, cycle threshold; HRV, human rhinovirus; NPA, nasopharyngeal aspirate; HSCT, hematopoietic stem cell transplant; AML, 
acute myelocytic leukemia; RSV, respiratory syncytial virus. 
Figure 1. Phylogenetic analysis of the viral protein (VP) 4/VP2 
region of the 5 enterovirus 104 (EV-104) strains belonging to the 
human enterovirus C (HEV-C) species (delimited by circular dotted 
line), along with the reference strain from Switzerland (GenBank 
accession no. EU840733). Prototype strains are also reported 
for the different HEV and human rhinovirus (HRV) species. CV, 
coxsackievirus; E, echovirus; PV, poliovirus.  Scale bar indicates 
nucleotide substitutions per position.reported. Obviously, the range of EV-104 pathogenicity 
will have to be deﬁ  ned in an extended clinical and epide-
miologic survey. However, virus detection in patient Pav-5 
in the absence of clinical symptoms indicates a potential 
nonpathogenic role for this virus, as is already known for 
HEVs, HRVs, and other respiratory viruses. In contrast, 
the sustained persistence of EV-104 in the respiratory tract 
of patient Pav-5 indicates that, at least in immunocompro-
mised patients, virus can be shed for a long period, as has 
been shown for other respiratory viruses in this patient pop-
ulation (15). We found also that the 2 immunocompetent 
persons (Pav-2 and Pav-4) had a chronic respiratory infec-
tion; however, because of limited sampling, the persistence 
of EV-104 was not shown.
From a methodologic standpoint, we believe it is rea-
sonable to conclude that, although only VP1 has been fully 
validated in multiple laboratories as the optimal typing re-
gion, other genome regions that code for capsid proteins 
may be ampliﬁ  ed to enable typing of known or even un-
known HEV genotypes. This method could facilitate the 
detection of new virus genotypes.
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